Here, we examined the therapeutic effects of chidamide, a new histone deacetylase (HDAC) inhibitor, on the cell and mouse models of rituximab/chemotherapy resistant B-cell lymphoma. The gene discussed is HDAC9; the disease is B-cell non-Hodgkin lymphoma.